Mallinckrodt (MNK) wins IPR decisions on INOMax blood-vessel drug - Bloomberg
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Mallinckrodt (NYSE: MNK) wins IPR decisions on INOMax blood-vessel drug, according to Bloomberg.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flowers Foods (FLO) and Flowers Baking Reach Settlement in Class Action Lawsuit
- CNH Industrial N.V. (CNHI) Says it Was Subject of Fabricated Press Release
- Las Vegas Sands (LVS) volatility elevated, Macau denies report of daily ATM withdrawal limit, Bloomberg reports
Create E-mail Alert Related CategoriesLitigation, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!